Want to see HK:1952 full AI Analyst Report?
Top Page
Everest Medicines Ltd.
(1952)
Select Model
Select Model
Rating:58Neutral
Price Target:
HK$34.00
▼(-33.98% Downside)
Action:Reiterated
Date:08/26/26
The score is driven primarily by mixed financials: very strong revenue growth and a solid balance sheet are offset by ongoing losses and continued negative free cash flow. Technicals are a clear positive with price above major moving averages and supportive momentum. Valuation remains a headwind given the negative P/E and lack of dividend yield data.
Positive Factors
Rapid revenue growth with healthy gross margin
The sharp revenue increase indicates rapid commercial expansion and stronger product adoption. Maintaining a gross margin near 60% provides meaningful room to fund selling, research, and operating costs, supporting the potential for improving profitability as scale develops.
Negative Factors
Persistent operating and net losses
The company has not yet converted strong revenue growth into sustainable earnings. Continuing operating and net losses can absorb equity capital, limit internally funded investment, and make future performance dependent on achieving further scale or improving cost efficiency.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid revenue growth with healthy gross margin
The sharp revenue increase indicates rapid commercial expansion and stronger product adoption. Maintaining a gross margin near 60% provides meaningful room to fund selling, research, and operating costs, supporting the potential for improving profitability as scale develops.
Read all positive factors
Everest Medicines Ltd. (1952) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$11.08B
Dividend YieldN/A
Average Volume (3M)12.71M
Price to Earnings (P/E)―
Beta (1Y)0.69
Revenue Growth192.64%
EPS Growth92.31%
CountryHK
Employees812
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.16
Shares Outstanding354,077,330
10 Day Avg. Volume14,124,374
30 Day Avg. Volume12,706,147
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)2.09
Price to Sales (P/S)6.51
P/FCF Ratio-64.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$50.40Price Target Upside-2.13% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.97
Revenue Forecast (FY)HK$3.19B
Everest Medicines Ltd. Business Overview & Revenue Model
Company Description
Everest Medicines Limited operates as a biopharmaceutical firm, concentrating its efforts on bringing innovative treatments to market. The company handles the entire process, from identifying and acquiring promising drug candidates to developing t...
Everest Medicines Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.41B | 1.71B | 706.68M | 125.93M | 12.79M | 54.00K |
| Gross Profit | 1.68B | 1.18B | 528.89M | 91.52M | 8.15M | 31.00K |
| EBITDA | 38.82M | -211.18M | -670.04M | -744.63M | -198.91M | -972.78M |
| Net Income | -53.92M | -297.77M | -1.04B | -844.46M | -247.28M | -1.01B |
Balance Sheet | ||||||
| Total Assets | 8.45B | 6.84B | 4.96B | 5.77B | 6.61B | 6.65B |
| Cash, Cash Equivalents and Short-Term Investments | 2.04B | 2.73B | 1.60B | 2.35B | 1.65B | 2.64B |
| Total Debt | 1.99B | 925.98M | 575.61M | 510.63M | 534.64M | 485.03M |
| Total Liabilities | 3.22B | 1.53B | 886.05M | 804.10M | 960.25M | 753.83M |
| Stockholders Equity | 5.23B | 5.31B | 4.07B | 4.97B | 5.65B | 5.89B |
Cash Flow | ||||||
| Free Cash Flow | -281.69M | -172.32M | -744.92M | -1.04B | -1.59B | -1.71B |
| Operating Cash Flow | -183.59M | -109.96M | -679.51M | -769.19M | -1.16B | -729.94M |
| Investing Cash Flow | -2.19B | -674.78M | 974.40M | 752.50M | -1.03B | -975.82M |
| Financing Cash Flow | 2.64B | 1.75B | 37.80M | 10.10M | -25.31M | -76.51M |
Everest Medicines Ltd. Technical Analysis
Positive
51.50
Price Trends
28.59
Positive
29.85
Positive
35.10
Negative
Market Momentum
1.30
Positive
55.11
Neutral
16.37
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1952, the sentiment is Positive. The current price of 51.5 is above the 20-day moving average (MA) of 31.92, above the 50-day MA of 28.59, and above the 200-day MA of 35.10, indicating a neutral trend. The MACD of 1.30 indicates Positive momentum. The RSI at 55.11 is Neutral, neither overbought nor oversold. The STOCH value of 16.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1952.
Everest Medicines Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$22.12B | 24.32 | 12.35% | ― | 117.39% | ― | |
58 Neutral | HK$11.08B | -178.94 | -1.02% | ― | 192.64% | 92.31% | |
52 Neutral | HK$22.80B | -14.63 | -27.40% | ― | 5.38% | 16.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$2.22B | 37.44 | 6.51% | ― | 605.95% | ― | |
47 Neutral | HK$9.55B | -19.57 | -43.54% | ― | 116.67% | -0.42% | |
46 Neutral | HK$33.87B | -76.96 | -7.32% | ― | 34.83% | 58.94% |
* Healthcare Sector Average
HK:1952
Everest Medicines Ltd.
31.22
-28.98
-48.14%
HK:9688
Zai Lab Ltd
20.00
-4.60
-18.70%
HK:6996
Antengene Corporation Limited
3.45
-4.28
-55.37%
HK:9969
InnoCare Pharma Ltd.
14.48
-2.89
-16.64%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.64
-17.28
-49.48%
HK:2616
CStone Pharmaceuticals
6.17
-5.64
-47.75%
Everest Medicines Ltd. Corporate Events
Everest Medicines Wins China Approval for First Self-Administered PSVT Nasal Spray
Sep 3, 2026
Everest Medicines has secured approval from China’s National Medical Products Administration for CARDAMYST (etripamil), a self-administered nasal spray to convert acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus...
Everest Medicines Publishes Unaudited Interim Results for First Half of 2026
Aug 18, 2026
Everest Medicines Limited has released its unaudited interim results for the six months ended 30 June 2026, in line with Hong Kong Stock Exchange listing requirements. The interim report, reviewed by the audit committee and Ernst Young, is availa...
Everest Medicines Sets Out Board Structure and Key Governance Committees
Aug 14, 2026
Everest Medicines Limited, a Cayman Islands-incorporated and Hong Kong-listed biopharmaceutical company, develops and commercializes innovative therapies and is overseen by a board that includes executive leadership for operations and finance alon...
Everest Medicines Reshapes Board With Director Resignation and New Appointment
Aug 14, 2026
Everest Medicines announced that non-executive director William Ki Chul Cho will resign effective 14 August 2026 to focus on other business interests, with no disagreements reported with the board or issues requiring shareholder attention. The boa...
Everest Medicines Sets Board Meeting to Approve 2026 Interim Results
Aug 5, 2026
Everest Medicines Limited has scheduled a board meeting for 18 August 2026 to review and approve the group’s interim financial results for the six months ended 30 June 2026. The meeting will also address other corporate matters, signaling ro...
Everest Medicines Grants New Options and Share Awards Under 2026 Scheme
Jul 17, 2026
Everest Medicines has granted 473,178 share options and 1,398,527 share awards to 14 senior managers and employees under its 2026 Share Scheme, with options priced at HK$28.052 against a market price of HK$24.72. The options have a seven-year exer...
Everest Medicines Closes High-Value BTK Inhibitor Deal With Travere
Jul 7, 2026
Everest Medicines has closed its exclusive license and collaboration agreement with Travere Therapeutics, triggering an upfront payment of US$112.5 million to the licensor and making Travere eligible for up to US$1.03 billion in development, regul...
Everest Medicines Wins Shareholder Backing for All AGM Resolutions
Jun 26, 2026
Everest Medicines reported that all resolutions tabled at its 26 June 2026 annual general meeting, held virtually, were approved by shareholders via poll. Investors backed the adoption of the 2025 financial statements, re-election of key executive...
Everest Medicines to Commercialize Hainan Herui’s Budesonide Capsules in Mainland China
Jun 24, 2026
Everest Medicines has entered a commercialization collaboration with Hainan Herui Pharmaceutical to launch Hainan Herui’s budesonide enteric capsules in mainland China, with Everest responsible for commercialization and quality oversight. Th...
Everest Medicines’ Major Shareholder Boosts Stake, Signaling Confidence in Long-Term Outlook
Jun 17, 2026
Everest Medicines Limited has seen its substantial shareholder CBC Group increase its stake by purchasing 712,000 shares between 16 and 17 June 2026 for about HK$19.2 million, at an average price of roughly HK$26.99 per share. Since December 2025,...
Everest Medicines Shareholders Approve Key Share Purchase Agreement
Jun 17, 2026
Shareholders of Everest Medicines Limited have approved a key Share Purchase Agreement at an extraordinary general meeting held virtually on 17 June 2026. The ordinary resolution passed with 76.14% of votes in favor and 23.86% against, following r...
Everest Medicines Takes Exclusive Asia Rights to Dimerix Kidney Drug DMX-200
Jun 15, 2026
Everest Medicines has secured an exclusive license from Australia’s Dimerix Limited to develop and commercialize DMX-200, a Phase 3 small-molecule CCR2 inhibitor for focal segmental glomerulosclerosis, across Greater China, South Korea and p...
Everest Medicines Substantial Shareholder CBC Group Raises Stake
Jun 9, 2026
Everest Medicines said substantial shareholder CBC Group, associated with non-executive director and honorary chairman Wei Fu, has increased its stake by purchasing 679,000 shares on the market between 8 and 9 June 2026 for about HK$18.9 million a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.